Avesthagen Limited, Bangalore-based systems biology life sciences company, has announced the acceleration of its Avestagenome Project. Thisresearch study focuses on the Indian and Parsi communities and the aim is to understand the linkage between genes, environmental factors, and disease, with an initial look into the role of smoking in developing lung, oral and oesophageal cancers.

Since 2008, the Avestagenome Project has been collecting a biobank of Parsi blood samples and extensive patient data from over 4,500 members of this community with a target of 15,000 Parsis globally by 2021. The molecular basis of longevity and age-related disorders, prioritising cancers, cardiovascular disease, diabetes and neurological disorders will be investigated in this cohort specifically. The project will provide insights into disease prediction and accelerate identification and development of biomarkers, predictive diagnostic tests, new drugs, and therapies.

Recognising the importance of the Parsi cohort and the unique systems' biology approach to research, the U.S.-basedFoundation for a Smoke-Free World, whose mission is to end smoking within this generation, recently awarded a grant to Avesthagen Limitedto prioritise research into lung and tobacco-related cancers.

Avesthagen will combine liquid biopsy, next-generation sequencing (NGS), state-of-the-art bioinformatics, artificial intelligence and machine learning to identify predictive and early-stage biomarkers of cancers in smokers. The project will use non-Parsi smoker and non-smoker samples from the wider Indian and other populations to gain further insights into the evidence behind such data.

Dr.VillooMorawala-Patell, Founder and Chairman, of Avesthagen said, “More than one million people die each year due to tobacco in India and currently there is limited research to help identify early biomarkers of smoking-related disease. We believe our study will identify novel biomarkers that could be used as predictive diagnostics for susceptibility to lung and other cancers. We are committed to employing the most advanced research methods available to drive the development of treatments that truly save lives. I am dedicated to improve the lives of people across the world.”

Clinical research uses liquid biopsy and systems biology approach to deliver predictive biomarkers for smoking-related diseases